Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

about

Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

P2860

Q34640358-23B7A279-92B1-4439-935B-8ADA11F4B46C Q35262607-65F6EBE0-C925-4F95-862C-F9DE2638742F

P2860

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Item

http://www.wikidata.org/entity/Q37813420

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Development, clinical utility, ...... of invasive fungal infections.

@en

Development, clinical utility, ...... of invasive fungal infections.

@nl

type

Item

label

Development, clinical utility, ...... of invasive fungal infections.

@en

Development, clinical utility, ...... of invasive fungal infections.

@nl

prefLabel

Development, clinical utility, ...... of invasive fungal infections.

@en

Development, clinical utility, ...... of invasive fungal infections.

@nl

P1476

Development, clinical utility, ...... of invasive fungal infections.

@en

P2093

Connie Valente

http://www.w3.org/2001/XMLSchema#string

Emily Zoller

http://www.w3.org/2001/XMLSchema#string

Kyle Baker

http://www.w3.org/2001/XMLSchema#string

Michael E Klepser

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

P304

299-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S7773

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21116336

http://www.w3.org/2001/XMLSchema#string

P921

fungal infectious disease

P932

2990390

http://www.w3.org/2001/XMLSchema#string

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

about

P2860

P2860

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932